Ftse Mib
34.151,41
-0,27%
DAX
18.498,38
0,32%
S&P 500
5.187,67
0,00%
NASDAQ
16.302,76
-0,18%
Bitcoin
61.239,43
-1,76%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ligand Pharmaceuticals Incorporated (LGND) Ligand Pharmaceuticals Incorporated (LGND) Notizie

LGND

Ligand Pharmaceuticals (LGND)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LGND
DataOraFonteTitoloSimboloCompagnia
07/03/202419:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
06/03/202400:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202422:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/02/202422:49Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
27/02/202413:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
14/02/202412:26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
13/02/202421:39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
11/01/202401:30GlobeNewswire Inc.Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy LasofoxifeneNASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/01/202423:40Dow Jones NewsLigand Pharmaceuticals Gets FDA OK for Viral Skin Infection TreatmentNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/12/202314:20GlobeNewswire Inc.Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical IndicationsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
28/11/202315:01GlobeNewswire Inc.Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer SymposiumNASDAQ:LGNDLigand Pharmaceuticals Incorporated
10/11/202303:48Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
09/11/202323:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
06/11/202315:00GlobeNewswire Inc.Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 TrialNASDAQ:LGNDLigand Pharmaceuticals Incorporated
18/10/202314:00GlobeNewswire Inc.Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026NASDAQ:LGNDLigand Pharmaceuticals Incorporated
02/10/202315:00GlobeNewswire Inc.Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast CancerNASDAQ:LGNDLigand Pharmaceuticals Incorporated
26/09/202300:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/07/202314:45GlobeNewswire Inc.Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 ProtectionNASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/06/202315:00GlobeNewswire Inc.Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual MeetingNASDAQ:LGNDLigand Pharmaceuticals Incorporated
21/06/202315:29Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
09/06/202323:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/06/202315:01GlobeNewswire Inc.Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast CancerNASDAQ:LGNDLigand Pharmaceuticals Incorporated
25/05/202323:00GlobeNewswire Inc.Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023NASDAQ:LGNDLigand Pharmaceuticals Incorporated
16/05/202319:15Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
08/05/202322:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
26/04/202318:25Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
20/04/202322:10Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
20/04/202322:08Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
20/04/202322:08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
22/02/202322:01Business WireLigand Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LGND

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
RACE
Ferrari NV
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
CPR
Davide Campari
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
FBK
Finecobank
BIT
TRN
Terna Trasmissione Elett...
BIT
IRE
Iren
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network